Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
NCT05620693Recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-NY-ESO-1 TCR-T in soft tissue sarcoma (STS), sponsored by Shenzhen University General Hospital. Primary endpoint: Adverse Events and Serious Adverse Events at 30 days. Started Nov 2022; status: recruiting.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05620693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620693.